Literature DB >> 8806198

Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance.

B J Schmitz-Dräger1, F Jankevicius, R Ackermann.   

Abstract

Recent molecular biology investigations have demonstrated that tumor progression and dissemination in bladder cancer is a highly complicated phenomenon, consisting of multiple distinct steps and regulated by a great number of different genes. Some of these genes involved in the specific steps of tumor progression and dissemination have been identified. Several oncogenes, e.g., the epithelial growth factor receptor (EGF-R), and tumor-suppressor genes, e.g., the p53 gene, have been found to correlate significantly with tumor progression. The decreased expression of cell-adhesion molecules such as E-cadherin appears to facilitate tumor-cell detachment in the primary tumor, whereas expression of the intercellular adhesion molecule (ICAM)-1 might be of relevance for cell attachment at the metastatic site. Tumor invasion through the basement membrane has been correlated with a decreased expression of laminin and elevated urinary levels of acidic fibroblast growth factor. Although the complex processes related to dissemination are far from being completely understood, the finding of differential expression of distinct genes appears to provide the first targets for therapeutic intervention.

Entities:  

Mesh:

Year:  1996        PMID: 8806198     DOI: 10.1007/bf00186899

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  71 in total

1.  Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine.

Authors:  T Matsubara; R Saura; K Hirohata; M Ziff
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

2.  Relation between basement membrane degradation and serum levels of laminin P1 in patients with transitional cell carcinoma of the bladder.

Authors:  K M Abou Farha; P P Menheere; F H Nieman; R A Janknegt; J W Arends
Journal:  Urol Int       Date:  1993       Impact factor: 2.089

3.  Expression of the retinoblastoma gene product in bladder carcinoma cells associates with a low frequency of tumor formation.

Authors:  D W Goodrich; Y Chen; P Scully; W H Lee
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

4.  Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells.

Authors:  J N Gordon; W P Shu; R N Schlussel; M J Droller; B C Liu
Journal:  Cancer Res       Date:  1993-10-15       Impact factor: 12.701

5.  Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.

Authors:  P P Bringuier; R Umbas; H E Schaafsma; H F Karthaus; F M Debruyne; J A Schalken
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

6.  Expression of the VLA beta 1 integrin family in bladder cancer.

Authors:  M Liebert; R Washington; J Stein; G Wedemeyer; H B Grossman
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

7.  Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors.

Authors:  D W Ye; J F Zheng; S X Qian; Y J Ma
Journal:  Urol Res       Date:  1993-01

Review 8.  Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder.

Authors:  Y Fradet; L Lafleur; H LaRue
Journal:  J Cell Biochem Suppl       Date:  1992

9.  Urine laminin P1 assessment discriminates between invasive and noninvasive urothelial cell carcinoma of the bladder.

Authors:  K M Abou Farha; P P Menheere; F H Nieman; R A Janknegt; J W Arends
Journal:  Urol Int       Date:  1993       Impact factor: 2.089

10.  Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies.

Authors:  R E Banks; A J Gearing; I K Hemingway; D R Norfolk; T J Perren; P J Selby
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.